Read by QxMD icon Read

Ascorbic acid hemodialysis

Miguel Moyses-Neto, Bruno Rafael Santos Brito, Dyego José de Araújo Brito, Noelia Dias Carneiro Barros, Márcio Dantas, Natalino Salgado-Filho, Roberto Silva Costa, Gyl Eanes Barros Silva
BACKGROUND: Ingestion of vitamin C is generally regarded as harmless. Oxalate nephropathy is an infrequent condition and is characterized by oxalate deposition in the renal tubules, in some cases resulting in acute kidney injury. It can be caused by overproduction of oxalate in genetic disorders and, more frequently, as a secondary phenomenon provoked by ingestion of oxalate or substances that can be transformed into oxalate in the patient. CASE PRESENTATION: We present a case of acute oxalate nephropathy in a 59-year-old black male with type 2 diabetes mellitus, who received a kidney transplant 11 years prior...
October 12, 2018: BMC Nephrology
Guibao Ke, Junlin Huang, Yue Zhu, Jia Yang, Yamei Zhang, Lvlin Chen, Juan Hu, Shaoqiang Tao, Yao Hu, Dehua Yang, Shuangxin Liu
BACKGROUND/AIMS: Hemodialysis (HD) patients often have inadequate nutrition, especially with respect to ascorbic acid (AA). It is reported that every HD session may cause a 50%- 75% decrease in plasma AA levels. Some studies have shown that supplementation of AA can change the outcome of chronic kidney disease-mineral bone disorders (CKD-MBD), but the effect of AA on HD patients with CKD-MBD remains controversial. Consequently, we decided to perform a meta-analysis to evaluate the efficacy of AA supplementation in CKD-MBD patients requiring dialysis...
2018: Kidney & Blood Pressure Research
N Nand, A R Deshmukh, R Mittal
OBJECTIVE: This study was planned to evaluate the effect of short term intravenous ascorbic acid on reducing ferritin and erythropoietin resistance in patients of chronic kidney disease (CKD) on maintenance haemodialysis (MHD). METHODS: Forty adult patients [20 patients in group A with increased serum ferritin level (>500 ng/ml), transferrin saturation (TSAT) ≤20% and 20 patients in group B with normal serum ferritin level (<200 ng/ml), TSAT ≤20%] of end stage renal disease (ESRD) with erythropoietin hyporesponsiveness undergoing maintenance hemodialysis were included in the study...
July 2017: Journal of the Association of Physicians of India
Ghada Mohamed El Mashad, Hanan M ElSayed, Nahla A Nosair
Children with end-stage renal disease (ESRD) suffer from dyslipidemia and hyperuricemia that might play a causal role in the progression of cardiovascular disease (CVD). The aim of the study is to assess the effects of Vitamin C supplementation on uric acid, ascorbic acid, and serum lipid levels among children on hemodialysis (HD). This prospective study was conducted in the pediatric nephrology unit at Menoufia University Hospital. The study included a total of 60 children with ESRD on maintenance HD therapy...
November 2016: Saudi Journal of Kidney Diseases and Transplantation
Yuguan Liu, Lawrence S Weisberg, Craig B Langman, Amanda Logan, Krystal Hunter, Deepali Prasad, Jose Avila, Thaliga Venkatchalam, Jeffrey S Berns, Garry J Handelman, William D Sirover
OBJECTIVES: Ascorbic acid (AA) supplementation may increase hemoglobin levels and decrease erythropoiesis-stimulating agent dose requirement in patients with end stage renal disease (ESRD). While plasma AA levels >100μM may be supratherapeutic, levels of at least 30μM may be needed to improve wound healing and levels may need to reach 70μM to optimize erythropoiesis. Of concern, oxalate (Ox), an AA metabolite, can accumulate in ESRD. Historically, if plasma Ox levels remain ≥30μM, oxalosis was of concern...
October 2016: Clinical Biochemistry
Dae Woong Kang, Chi Yong Ahn, Bong Kwan Ryu, Byung Chul Shin, Jong Hoon Chung, Hyun Lee Kim
BACKGROUND: Hemodialysis (HD) patients with functional iron deficiency often develop resistance to recombinant human erythropoietin (rhEPO). Recent studies have shown that intravenous ascorbic acid (IVAA) administration could override rhEPO resistance in HD patients. This study was undertaken to test the effects of IVAA in HD patients with normoferritinemic functional iron deficiency accompanied by EPO-hyporesponsive anemia. METHODS: Fifty-eight HD patients with normoferritinemic anemia (between 100 and 500 μg/L) were included and divided into the control (N=25) and IVAA (N=33) groups...
March 2012: Kidney Research and Clinical Practice
Tetsuya Ogawa, Kosaku Nitta
Approximately 5-10% of patients with end-stage renal disease (ESRD) exhibit hyporesponsiveness to erythropoiesis-stimulating agents (ESAs), defined as a continued need for higher than 300 IU/kg/week doses of epoetin or a 1.5 mg/kg/week dose of darbepoetin. ESA hyporesponsiveness contributes to the morbidity, mortality and health-care economic burden of ESRD patients. The most common causes of ESA resistance are absolute or functional iron deficiency and inflammation. Maintaining adequate iron stores is clearly accepted as the most important strategy for reducing the ESA requirement and for enhancing ESA efficacy...
2015: Contributions to Nephrology
Marcello Tonelli, Natasha Wiebe, Stephanie Thompson, David Kinniburgh, Scott W Klarenbach, Michael Walsh, Aminu K Bello, Labib Faruque, Catherine Field, Braden J Manns, Brenda R Hemmelgarn
BACKGROUND: People with kidney failure are often deficient in zinc and selenium, but little is known about the optimal way to correct such deficiency. METHODS: We did a double-blind randomized trial evaluating the effects of zinc (Zn), selenium (Se) and vitamin E added to the standard oral renal vitamin supplement (B and C vitamins) among hemodialysis patients in Alberta, Canada. We evaluated the effect of two daily doses of the new supplement (medium dose: 50 mg Zn, 75 mcg Se, 250 IU vitamin E; low dose: 25 mg Zn, 50 mcg Se, 250 IU vitamin E) compared to the standard supplement on blood concentrations of Se and Zn at 90 days (primary outcome) and 180 days (secondary outcome) as well as safety outcomes...
April 11, 2015: BMC Nephrology
Cristina Gluhovschi, Mirela Modilcă, Mihaela Margineanu, Gh Gluhovschi, Silvia Velciov, Ligia Petrica, Emilia Barzuca, Florica Gădălean, S Ivascu, Adriana Kaycsa, Cristina Ghiocel
AIMS: End Stage Renal Disease (ESRD) represents a microinflammatory state accompanied by oxidative stress and an imbalance between pro- and antioxidants. Vitamin C is a highly effective antioxidant, acting to lessen oxidative stress. The aim of our study was to assess the Antioxidant Capacity of Water soluble substances (ACW) and the Antioxidant Capacity of Liposoluble substances (ACL) in patients with Balkan Endemic Nephropathy (BEN) on hemodialysis undergoing Vitamin C therapy as compared to healthy controls...
2014: Romanian Journal of Internal Medicine, Revue Roumaine de Médecine Interne
William D Sirover, Yuguan Liu, Amanda Logan, Krystal Hunter, Robert L Benz, Deepali Prasad, Jose Avila, Thaliga Venkatchalam, Lawrence S Weisberg, Garry J Handelman
OBJECTIVE: To determine the prevalence of vitamin C (ascorbic acid [AA]) deficiency in patients with end-stage renal disease, the effect of supplemental AA on plasma AA concentrations, and the extrinsic and intrinsic factors that affect plasma AA concentrations in this patient population. DESIGN: In study 1, we compared the effect of hemodialysis (HD) on plasma AA concentrations between patients with low and high pre-HD AA concentrations. In study 2, we analyzed kinetic and nonkinetic factors for their association with increased plasma AA concentrations in patients on maintenance HD...
May 2015: Journal of Renal Nutrition
Takahiro Kuragano, Mana Yahiro, Aritoshi Kida, Minoru Furuta, Yasuyuki Nagasawa, Yukiko Hasuike, Masayoshi Nanami, Takeshi Nakanishi
PURPOSE: We evaluate the effect of the protoconized anemia therapy on adverse events using the Hb and ferritin levels of individual patients undergoing maintenance hemodialysis (MHD). METHODS: Design: A randomized, parallel group, multi-center study. PATIENTS: Two hundred sixty-six MHD patients. Intervention group: The doses of erythropoietin, iron, and vitamin C were adjusted every month based on the ferritin and hemoglobin (Hb) levels according to the protocol...
December 2014: International Journal of Artificial Organs
Johnathan S de Freitas, Paulo Sucasas Costa, Luciane Rezende Costa, Alessandra V Naghettini
OBJECTIVE: To identify the occurrence of anemia in pediatric patients on hemodialysis and the association between hemoglobin levels and anemia in CKD-related variables. METHODS: This was a retrospective study. Patients aged up to 18 years with chronic kidney disease undergoing hemodialysis at this service between January of 2009 and December of 2010 were selected. Clinical and laboratory data were obtained from medical records. Statistical analysis was performed with chi-squared test, Student's t-test and general estimating equations (GEE) using SPSS 20...
January 2015: Jornal de Pediatria
Vajihe Biniaz, Ali Tayebi, Abbas Ebadi, Mehdi Sadeghi Shermeh, Behzad Einollahi
INTRODUCTION: Clinical studies of recent years have shown that hyperuricemia is associated with poor outcomes such as cardiovascular mortality and dialysis inadequacy in patients undergoing hemodialysis. Our study investigated the effect of vitamin C supplementation on serum uric acid levels in hemodialysis patients. MATERIALS AND METHODS: This randomized placebo-controlled trial was conducted on 172 hemodialysis patients. They were randomly divided into the intervention group, to receive 250 mg of vitamin C, three times per week, for 8 weeks, and control groups 1 and 2, to receive placebo injection (saline) and no intervention, respectively...
September 2014: Iranian Journal of Kidney Diseases
Christian Henning, Kristin Liehr, Matthias Girndt, Christof Ulrich, Marcus A Glomb
Maillard α-dicarbonyl compounds are known as central intermediates in advanced glycation end product (AGE) formation. Glucose is the primary source of energy for the human body, whereas l-threo-ascorbic acid (vitamin C) is an essential nutrient, involved in a variety of enzymatic reactions. Thus, the Maillard degradation of glucose and ascorbic acid is of major importance in vivo. To understand the complex mechanistic pathways of AGE formation, it is crucial to extend the knowledge on plasma concentrations of reactive key α-dicarbonyl compounds (e...
October 10, 2014: Journal of Biological Chemistry
Maurizio Bossola, Enrico Di Stasio, Antonella Viola, Alessandra Leo, Giusy Carlomagno, Tania Monteburini, Stefano Cenerelli, Stefano Santarelli, Rolando Boggi, Giacinto Miggiano, Carlo Vulpio, Cristina Mele, Luigi Tazza
PURPOSE: We aimed to estimate dietary intakes of trace elements, minerals, and vitamins in hemodialysis patients (HDP) of three centers in one metropolitan and two urban areas of Italy. METHODS: Daily dietary intake was assessed using a 3-day diet diary in 128 HDP. RESULTS: Mean daily intakes of trace elements were as follows: zinc, 7.6 ± 5.4 mg; copper, 14.3 ± 11.8 mg; selenium, 28.3 ± 18.1 μg; and iron, 7.2 ± 4.1 mg (7.8 ± 2.6 mg in women, 6...
April 2014: International Urology and Nephrology
S Yaich, Y Chaabouni, K Charfeddine, S Zaghdane, M Kharrat, K Kammoun, S Makni, T Boudawara, J Hachicha
Renal oxalate deposition can be seen with primary hyperoxaluria, malabsorptive states, ethylene glycol toxicity and, rarely, with excessive vitamin C ingestion. We report a case of secondary hyperoxaluria in which the diagnosis was not considered initially because there was no past history of urinary calculi and no evidence of nephrocalcinosis on plain X-ray of the abdomen and ultrasonography. The disease was detected and diagnosed only after kidney transplantation. Secondary oxalosis can cause graft loss or delayed graft function...
January 2014: Saudi Journal of Kidney Diseases and Transplantation
Omid Sedighi, Atieh Makhlough, Ghasem Janbabai, Mohammad Neemi
BACKGROUND: Functional iron deficiency (FID) may cause erythropoietin resistance in patients under hemodialysis (HD). Since the role of chronic inflammation or oxidative stress in its pathogenesis is unclear, controversy remains to whether intravenous iron or intravenous ascorbic acid (an antioxidant) can improve this anemia due to decreased iron availability. OBJECTIVES: The current study compared the effect of intravenous iron versus intravenous ascorbic acid in the management of FID in HD patients...
September 2013: Nephro-urology Monthly
KunYing Zhang, YinHui Li, XuYang Cheng, Li Liu, WenYing Bai, WeiYa Guo, LeiYun Wu, Li Zuo
BACKGROUND: Both vitamin C deficiency and inflammation are prevalent in maintenance hemodialysis (MHD) patients. In this study, we aimed to elucidate the effect of oral vitamin C supplementation on inflammatory status in MHD patients with low vitamin C level and high hypersensitive C-reactive protein (hs-CRP) level. METHODS: A total of 128 patients were recruited in our present study. Patients were divided into two groups. In group 1 (n = 67), patients were orally administered with 200 mg/day vitamin C in the first 3 months, and then the vitamin C supplementation was withdrawn in the next 3 months...
November 14, 2013: BMC Nephrology
Soo Kyoung Kim, Jong Ryeal Hahm, Ho-Su Kim, Sungsu Kim, Tae Sik Jung, Jung Hwa Jung, Hye Ryun Lee, Deok Ryong Kim
We describe herein a case of life-threatening hypoglycemia due to spurious elevation of glucose concentration during the administration of ascorbic acid in a type 2 diabetic patient. A 31-year-old female was admitted for proliferative diabetic retinopathy treatment and prescribed high dose ascorbic acid. During hospitalization, she suddenly lost her consciousness and her glucose concentration was 291 mg/dL, measured using self-monitoring blood glucose (SMBG) device, while venous blood glucose concentration was 12 mg/dL...
September 2013: Yonsei Medical Journal
M Jalalzadeh, E Shekari, F Mirzamohammadi, M H Ghadiani
Resistance to recombinant erythropoietin (rEPO) in hemodialysis patients may be due to inadequate iron recruitment and defect in iron use. In this cross over randomized clinical trial, 30 hemodialysis patients with serum ferritin levels of ≥500 ng/ml, hemoglobin ≤11.0 g/dl, and transferrin saturation (TSAT) of 20% or less were administrated intravenous iron (50-100 mg/wk) and rEPO (120-360 U/kg/wk) for 6 months. Patients were excluded if there was a clear explanation for rEPO hyporesponsiveness. Patients were divided into two groups...
May 2012: Indian Journal of Nephrology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"